Key Publications

(2026) Thomas T Poulsen, Olga Ilina, Jonathan H Wardman, Anne Bie, Jette Bornholdt, Mette Gillberg, Daniela Pontieri, Pernille Barkholt, Christophe Côme, Yue Zhang, Jianjian Zhang, Yixuan Wang, Huiyan Shi, Shu-Hui Liu, Xun Meng, Dominik Mumberg. ADCE-T02 – a Next Generation Antibody Drug Conjugate Targeting Tissue Factor Demonstrates Superior Preclinical Efficacy and Tolerability. Mol Cancer Ther. https://doi.org/10.1158/1535-7163.MCT-26-0045

(2026) Thomas T Poulsen, Olga Ilina, Pernille Barkholt et al., ADCE-T02 – A Clinical Stage Antibody Drug Conjugate Targeting Tissue Factor Demonstrates Strong Efficacy in Preclinical Models of Head and Neck Squamous Cell Carcinoma. Cancer Research https://adcendo.com/wp-content/uploads/ADCE-T02-AACR-2026-POSTER-FINAL.pdf 

(2025) Thomas T Poulsen, Yue Zhang, Jianjian Zhang et al., ADCE-T02: a Potential First- and Best-in-Class Topoisomerase-1 Inhibitor Based Antibody Drug Conjugate Against Tissue Factor Demonstrates Excellent Preclinical Efficacy and Tolerability. Cancer Research https://adcendo.com/wp-content/uploads/ADCE-T02-AACR-2025-FINAL-POSTER.pdf

(2023) Weining W, Tao M, Qianqian Z, Yi S, Guoxiang F, Jing S, Yue Z, Zhaohui W, Mingqiao W, Rong P, Linjie M, Caiwei C, Lijun W, Biao Z, Hui Z, Junyi P, Jianjian Z, Yi Peter H, Guoqiang H, Yu Q, Shu-Hui L, Wenhao H, Xun M. Antibody-Exatecan Conjugates with a Novel Self-immolative Moiety Overcome Resistance in Colon and Lung Cancer. Cancer Discovery, 2023 Apr 3;13(4):950-973. doi: 10.1158/2159-8290.CD-22-1368. PMID: 36693125 https://aacrjournals.org/cancerdiscovery/article-abstract/13/4/950/725002/Antibody-Exatecan-Conjugates-with-a-Novel-Self

(2022) de Bono JS, Harris JR, Burm SM, Vanderstichele A, Houtkamp MA, Aarass S, Riisnaes R, Figueiredo I, Nava Rodrigues D, Christova R, Olbrecht S, Niessen HWM, Ruuls SR, Schuurhuis DH, Lammerts van Bueren JJ, Breij ECW, Vergote I. Systematic study of tissue factor expression in solid tumors. Cancer Rep (Hoboken), 2023 Feb;6(2):e1699. doi: 10.1002/cnr2.1699. PMID: 36806722 https://onlinelibrary.wiley.com/doi/10.1002/cnr2.1699

(2026) Chao-Chi Wang*, Pernille Barkholt*, Agnieszka Wozniak et al., Molecular epidemiology of the expression of urokinase plasminogen activator receptor-associated protein (uPARAP) in mesenchymal malignancies. Transl Oncol  https://www.sciencedirect.com/science/article/pii/S1936523326000458?via%3Dihub

(2026) Kirstine S Nørregaard, Ida M E Larsen, Henrik J Jürgensen et al., The Recycling Collagen Receptor uPARAP Is a Unique Mediator of Stromal Drug Delivery to Carcinoma Cells. Mol Cancer Ther – https://aacrjournals.org/mct/article/25/1/140/771292/The-Recycling-Collagen-Receptor-uPARAP-Is-a-Unique

(2025) Jonathan H Wardman, Anne Bie, Christophe Come et al., ADCE-D01: A first-in-class antibody drug conjugate against urokinase plasminogen activator receptor-associated protein (uPARAP) demonstrates excellent preclinical efficacy and tolerability. Cancer Research.

(2024) Gregersen I, Loekke C, Lange JB, Barkholt P, Come C, Broberg T, Petersen MM, Lynch CM, Mumberg D, Behrendt N, Engelholm L. Urokinase plasminogen activator receptor-associated protein (uPARAP) is overexpressed in human glioblastomas and is a therapeutic target for antibody-drug conjugates (ADC). Cancer Research 84(6_Supplement):6355-6355. DOI:10.1158/1538-7445.AM2024-6355. 

(2023) Barkholt P, Wozniak A, Wang C-C; Lee C-J,De Kock L, Engelholm LH, Lynch C, Mumberg D, Schöffski P. The urokinase plasminogen activator receptor-associated protein (uPARAP) is an attractive target for the development of antibody-drug conjugates (ADCs) for treatment of mesenchymal malignancies. Cancer Res (2023) 83 (7_Supplement): 1547. https://doi.org/10.1158/1538-7445.AM2023-1547.

(2022) Gucciardo, F, Pirson S, Baudin L, Lebeau A, Noël A. uPARAP/Endo180: a multifaceted protein of mesenchymal cells. Cell Mol Life Sci 2022 Apr 22;79(5):255. doi: 10.1007/s00018-022-04249-7. PMID: 35460056 PMCID: PMC9033714. https://link.springer.com/article/10.1007/s00018-022-04249-7

(2022) Evans RJ, Perkins DW, Selfe J, Kelsey A, Birch GB, Shipley JM, Schipper K, Isacke CM. Endo180 (MRC2) Antibody-Drug Conjugate for the Treatment of Sarcoma. Mol Cancer Ther. 2023 Feb 1;22(2):240-253. doi: 10.1158/1535-7163.MCT-22-0312. PMID: 36399638. PMCID: PMC9890142. https://aacrjournals.org/mct/article/22/2/240/716263/Endo180-MRC2-Antibody-Drug-Conjugate-for-the

(2017) Nielsen CF, van Putten SM, Lund IK, Melander MC, Nørregaard KS, Jürgensen HJ, Reckzeh K, Christensen KR, Ingvarsen SZ, Gårdsvoll H, Jensen KE, Hamerlik P, Engelholm LH, Behrendt N. The collagen receptor uPARAP/Endo180 as a novel target for antibody-drug conjugate mediated treatment of mesenchymal and leukemic cancers. Oncotarget. 2017 Jul 4;8(27):44605-44624. doi: 10.18632/oncotarget.17883. PMID: 28574834; PMCID: PMC5546505. https://www.oncotarget.com/article/17883/text/

(2002) Schnack Nielsen B, Rank F, Engelholm LH, Holm A, Danø K, Behrendt N. Urokinase receptor-associated protein (uPARAP) is expressed in connection with malignant as well as benign lesions of the human breast and occurs in specific populations of stromal cells. Int J Cancer. 2002 Apr 10;98(5):656-64. doi: 10.1002/ijc.10227. PMID: 11920633.

(2000) Behrendt N, Jensen ON, Engelholm LH, Mørtz E, Mann M, Danø K. A urokinase receptor-associated protein with specific collagen binding properties. J Biol Chem. 2000 Jan 21;275(3):1993-2002. doi: 10.1074/jbc.275.3.1993. PMID: 10636902.